Management of the COPD Patient with Comorbidities: An Experts Recommendation Document

This article was published in the following Dove Press journal:
International Journal of Chronic Obstructive Pulmonary Disease

Background: Chronic obstructive pulmonary disease (COPD) is associated with multiple comorbidities, which impact negatively on patients and are often underdiagnosed, thus lacking a proper management due to the absence of clear guidelines.

Purpose: To elaborate expert recommendations aimed to help healthcare professionals to provide the right care for treating COPD patients with comorbidities.

Methods: A modified RAND-UCLA appropriateness method consisting of nominal groups to draw up consensus recommendations (6 Spanish experts) and 2-Delphi rounds to validate them (23 Spanish experts) was performed.

Results: A panel of Spanish internal medicine experts reached consensus on 73 recommendations and 81 conclusions on the clinical consequences of the presence of comorbidities. In general, the experts reached consensus on the issues raised with regard to cardiovascular comorbidity and metabolic disorders. Consensus was reached on the use of selective serotonin reuptake inhibitors in cases of depression and the usefulness of referring patients with anxiety to respiratory rehabilitation programmes. The results also showed consensus on the usefulness of investigating the quality of sleep, the treatment of pain with opioids and the evaluation of osteoporosis by lateral chest radiography.

Conclusion: This study provides conclusions and recommendations that are intended to improve the management of the complexity of patients with COPD and important comorbidities, usually excluded from clinical trials.

Keywords: chronic obstructive pulmonary disease, COPD, comorbidities, modified RAND-UCLA, Delphi technique

Introduction
Chronic obstructive pulmonary disease (COPD) is a serious health problem that constitutes the fourth cause of mortality worldwide. In Spain, its prevalence among the population between 40 and 80 years of age is 10.2%. COPD is related with multiple associated conditions and comorbidities which often share characteristics and risk factors. The comorbidities most commonly associated with COPD include cardiovascular disease, endocrine and metabolic disorders, neuropsychiatric diseases, anemia, neoplasms (especially lung cancer), and gastrointestinal diseases, conditions often linked with smoking, systemic inflammation, airflow limitation, and aging.

The presence of comorbidities impacts negatively on COPD patients, reducing quality of life and increasing the probability of hospital admission and mortality.
Indeed, the presence of more than 1 comorbidity more than doubles the risk of mortality, and many patients with COPD die because of their comorbidities rather than their COPD, particularly in the mild and moderate phases.4

The proper management of multimorbidity in patients with COPD involves the early detection and treatment of comorbidities. In this regard, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend evaluating separately the presence of comorbidities5 when assessing these patients.

Often, however, comorbidities in COPD are underdiagnosed, because of a lack of a standardized protocol for their determination and difficulties in differentiating comorbidities from severe COPD.6,7 Moreover, the influence of the different treatments indicated for comorbidities in COPD and vice versa remains unclear. The outcome is failure to treat patients according to their needs.3,7

In the absence of clear guidelines on the treatment of patients with COPD and comorbidities, these expert recommendations aim to help healthcare professionals treating these patients to provide the right care.

Methods
This project has been conducted using a qualitative synthesis of the scientific evidence and a modification of the RAND/UCLA appropriateness method,8 which combines Delphi consensus and nominal group techniques, collecting the agreement of a group of experts taking into account their clinical experience, the scientific evidence, and the collective judgment of the group.

Process Phases
1. Definition of working group and project and preparation of the consensus protocol. Preparation of the document began with the constitution of the team of 2 experts that made up the group coordinator (GC), and the recommendations preparation group (RPG), composed of 4 Spanish experts in internal medicine. All members of the working group (group coordinator and recommendations preparation group) belong to the COPD working group of the Spanish internal medicine society. The GC met in person and then held a kick-off meeting with the RPG to define the objectives and fundamental criteria of the consensus document (justification, objectives, scope, target population, topics, clinical questions to be answered, formulated according the PICO (Problem/Patient/Population, Intervention/Indicator, Comparison, Outcome) structure whenever possible, participants, and methodology) and the working protocol.

The recommendations validation group (RVG) was formed at a later date.

1. Rapid review of the literature. A non-exhaustive systematic review of the literature was conducted to identify the publications that could answer the consensus questions, using a search strategy that included studies published in the Medline database (PubMed) in the previous 5 years. The search was completed with publications relevant to the topic that the experts felt were of interest. Items for review were then selected and prioritized using two strategies, the first of which took into account title and abstract first, and then the complete document, type, and year of publication; the second strategy took into account title and abstract.

2. Critical reading and synthesis of information. The complete text of the selected articles was read critically, and the information was synthesized using templates which included a brief description of the study, design, patients, interventions used, main results, and conclusions. The studies were classified according to the quality of the work, using an adaptation of the Scottish Intercollegiate Guidelines Network developers’ handbook9 and sent to the RPG for reading, analysis, and preparation of recommendations.

3. Formulation of recommendations. After reading and analyzing the information, the RPG formulated the recommendations and conclusions that corresponded to each of the clinical questions, including the level of evidence and grade of recommendation according to the Oxford Centre for Evidence Based Medicine system.10

4. Consensus process. The process of debate and drawing up consensus recommendations consisted of an initial in-person consensus session, using nominal group methodology, in which participants defended or modified the recommendations as appropriate, and then voted on their inclusion in or exclusion from the document. The recommendations document subsequently underwent a process of external validation using a 2-round Delphi technique, in which 23 Spanish specialists participated in the first round, and 21 in the second. The panel of experts consisted of specialists in internal medicine from various hospitals.
and geographical areas of Spain belonging to the COPD working group of the Spanish society of internal medicine, selected according to the different hospital sizes (see acknowledgements). Their experience in the clinical management of COPD in their daily practice was taken into account for inclusion in the panel. In each round, the members of the RVG expressed their degree of agreement or disagreement with the recommendations in an online questionnaire on a Likert scale of 1 to 5 (1 being "strongly disagree" and 5 "strongly agree") and provided reasons for their response. Grades 1 and 2 on this scale were considered disagreement, grades 4 and 5 were taken as agreement, and grades 3 were neither agreement nor disagreement. According to this grouping, the recommendation document was prepared that contained the recommendations and conclusions of the RPG, together with the percentage of final agreement reached after the external validation rounds, which was validated by the CC and the RPG. Three recommendations/conclusions were deleted after inconsistencies were detected.

Evidence Summary and Recommendations

This document contains a total of 73 recommendations and 81 conclusions (Supplementary Tables 1–5) on the management of patients with COPD and comorbidities, which were agreed among the expert members of the RVG. These conclusions and recommendations are grouped for each comorbidity by clinical manifestations in the COPD patient (a) by the appropriate treatment of patients with COPD and each of the comorbidities assessed and (b) by the clinical management of COPD in their daily practice.

COPD as a Disease with Extrapulmonary Manifestations and Comorbidities

Obesity

The prevalence of obesity in COPD patients is between 20% and 43% depending on the region, field of study, and disease stage. Obesity causes respiratory function impairment, and patients with COPD and obesity have lower exercise capacity and lower quality of life than patients with COPD alone.

Cardiovascular Risk Factors

Obesity

Obesity is a cardiovascular risk factor in COPD patients. There is evidence that obesity in COPD patients is associated with an increased risk of cardiovascular events and all-cause mortality. Obese patients with COPD have a higher prevalence of cardiovascular comorbidities such as hypertension, diabetes, and cardiovascular disease.

References

1. Recio Iglesias et al. International Journal of Chronic Obstructive Pulmonary Disease 2020:15

Preparation of the recommendations document

Consensus process (validation of recommendations)

Preparation of recommendations (RPG)

Critical reading and synthesis of information

Rapid review of the literature

Definition of working group and project, and preparation of the consensus protocol

Figure 1 Process followed for the preparation of the consensus document.
changes\textsuperscript{15} that lead to a reduction in patients’ quality of life and exercise tolerance\textsuperscript{13,16} and an increase in the use of health resources.\textsuperscript{17} Patients with COPD and obesity should receive recommendations on nutrition and physical activity (Supplementary Table 2A).

Regarding the treatment of patients with COPD and obesity, the use of systemic corticosteroids can contribute to weight gain,\textsuperscript{18} while roflumilast can cause weight loss.\textsuperscript{19} Moreover, rehabilitation programs have been shown to produce equivalent improvements in obese and non-obese patients,\textsuperscript{20,21} so these programs are recommended in patients with COPD and obesity. In overweight or obese patients, a higher fat-free mass index is associated with greater exercise tolerance, so weight loss treatment for reducing weight while preserving lean body mass should be considered\textsuperscript{22} (Supplementary Table 2A).

**Arterial Hypertension**

Arterial hypertension (AHT) is the most common comorbidity in COPD patients\textsuperscript{23} It is associated with a greater degree of dyspnea, lower tolerance for physical activity,\textsuperscript{24} and airflow obstruction,\textsuperscript{25} and correlates inversely with lung function.\textsuperscript{26} Although AHT per se does not influence the natural history of COPD, it is a vascular risk factor for the development of cardiovascular disease.\textsuperscript{5} Thus, in patients with COPD, AHT can promote the onset of heart failure (HF), ischemic heart disease (IHD), or chronic kidney disease, which worsen the prognosis of COPD.\textsuperscript{4,27} A comprehensive examination must therefore be performed to detect the risk factors associated with COPD and AHT in all patients with both diseases (Supplementary Table 2B).

With regard to the appropriate treatment of patients with COPD and AHT, 2 conclusions and 4 recommendations were formulated (Supplementary Table 2B). Although no definitive conclusions can be made regarding the influence of long-acting bronchodilators (formoterol, salmeterol, indacaterol, tiotropium) and anti-inflammatory drugs (roflumilast, inhaled corticosteroids)\textsuperscript{28-30} on the control of AHT, it can be concluded that bronchodilators (LAMA and LABA) are safe and well tolerated in hypertensive patients with COPD.\textsuperscript{3}

According to evidence on the treatment of AHT in patients with COPD, calcium antagonists have no significant clinical effect on COPD,\textsuperscript{31} while both renin-angiotensin-aldosterone system inhibitors and beta-blockers (BBs) may provide a benefit.\textsuperscript{32,33} The use of cardioselective BBs is preferable if the patient has COPD and AHT, ICD, HF, or arrhythmias.\textsuperscript{34,35} Retrospective and observational studies have also shown that the use of BB in patients hospitalized for COPD exacerbations was well tolerated and associated with a 40% reduction in mortality,\textsuperscript{36} and a lower mortality rate and risk of exacerbation, respectively.\textsuperscript{37} Patients receiving diuretics and atenolol must be closely monitored, and treatment with potassium supplements or potassium-sparing diuretics in the first case,\textsuperscript{38} and reduction of doses of atenolol in the second,\textsuperscript{4} may be considered.

**Diabetes Mellitus**

The prevalence of diabetes mellitus (DM) in COPD patients is higher than in the general population, and an estimated 29.4%–37% of COPD patients hospitalized are diabetic.\textsuperscript{39,40} Diabetic patients also have an increased risk of COPD (as well as asthma, cystic fibrosis, and pneumonia), due to lung function decline and increased incidence of respiratory infections caused by chronic hyperglycemia.\textsuperscript{41}

DM has implications for COPD patients. In the first place, it has been associated with a lower quality of life in several studies,\textsuperscript{42-47} which has also been shown in a recent study to be the result of a decline in lung function and the consequent decrease in exercise tolerance.\textsuperscript{47} DM in COPD patients reduces time to first hospitalization, prolongs the length of stay, and increases mortality due to exacerbations,\textsuperscript{38} as a result of both greater numbers of exacerbations of infectious origin\textsuperscript{49} and poorer outcomes with non-invasive mechanical ventilation during these events.\textsuperscript{40} Furthermore, in the 24 months after hospitalization of patients with COPD and DM2 for exacerbations, the risk of mortality is twice that of those who do not have DM2\textsuperscript{27}, and an increase in 5-year mortality has also been reported.\textsuperscript{39,51,52} Another study found that DM in COPD increases mortality by 3-fold, regardless of lung function,\textsuperscript{53} and it is associated with restrictive changes in respiratory function that can lead to increased dyspnea and a greater predisposition to exacerbations.\textsuperscript{54} Based on this evidence, we recommend to rule out DM in COPD patients, and to maintain an optimal degree of glycemic control in COPD patients with DM (Supplementary Table 2C).

No specific recommendations are currently available for the treatment of DM in COPD patients,\textsuperscript{4} who can be managed according to standard guidelines,\textsuperscript{3-5} as reflected in our recommendation (Supplementary Table 2C). According to the available evidence, the use of systemic corticosteroids for acute COPD exacerbations is associated with an increased risk of hyperglycemia,\textsuperscript{55} an effect that does not occur with inhaled corticosteroids (ICS).\textsuperscript{56,57} Insufficient evidence is available on the effect of roflumilast on blood glucose.\textsuperscript{58} As in diabetic patients without COPD, metformin
is the first choice, and this drug must be suspended in the same situations as in diabetic patients without COPD. The adjustment of antidiabetic treatment and closer monitoring of blood glucose should be evaluated in diabetic patients with COPD3. (Supplementary Table 2C).

Dyslipidemia

The prevalence of dyslipidemia in patients with chronic obstructive pulmonary disease (COPD) varies widely, depending on the type of study and the criteria selected to establish the dyslipidemia diagnosis. The prevalence in Spain is around 35%59,60 although studies such as CONSISTE reported rates of up to 48%.61 According to several studies, COPD patients characteristically present a lipid pattern with similar total cholesterol and low density lipoprotein cholesterol (LDL-C), lower triglycerides (TG), and greater high-density lipoprotein cholesterol (HDL-C) values than the general population.4,62

Although the role of dyslipidemia in the clinical course of COPD is still unclear, it must be monitored, as it represents a risk factor for the development of cardiovascular disease in these patients.3 However, the available evidence is still insufficient to establish specific conclusions (Supplementary Table 2D).

Very few studies have evaluated the effect of the different COPD treatments on dyslipidemia. No significant clinical effects have been described with inhaled anticholinergics, and studies with methylxanthines and inhaled corticosteroids (ICS) point to an increase in total cholesterol and HDL-C with high doses of ICS in healthy patients4 and an increase in HDL-C in rheumatology patients receiving prednisone63 and inhaled beta-2 adrenergic agonists, such as terbutaline.64 The scientific evidence on lipid-lowering treatments in COPD is insufficient to establish solid recommendations on their use, as studies published to date vary widely in terms of statins and doses, and the follow-up period is generally limited.65,66 Among the effects observed, low-dose pravastatin was found to improve exercise tolerance in non-dyslipidemic patients,67 and in several studies, treatment with statins reduced the number of exacerbations68 in COPD patients with pulmonary hypertension69 and concomitant cardiovascular disease,70 as well as the number of hospitalizations.71,72 In 1 study, however, the number of exacerbations and time to first exacerbation did not decrease in patients who received simvastatin.68 The reduction in respiratory mortality and all-cause mortality does not appear to be due to the lipid-lowering effect of the statin, but rather to its antiinflammatory action.73 Reductions in respiratory mortality and all-cause mortality of 55% and 21%, respectively, have been reported in patients with COPD who received statins.74 Another study found no association between statin use, reduction of all-cause mortality, time to first hospitalization for exacerbation, or time to first pneumonia.75 A meta-analysis of 10 randomized clinical trials studying the effect of statins in COPD patients showed an improvement in exercise tolerance, lung function, and quality of life in COPD patients with a history of cardiovascular disease treated with statins.76 Given this evidence, our conclusions and recommendations about dyslipidemia in COPD patients are shown in Supplementary Table 2D.

Concomitant Cardiovascular Disease

Heart Failure

The prevalence of heart failure (HF) ranges from 5% to 60% in the general COPD population,77 and increases in line with COPD severity, being approximately 30% in patients hospitalized for COPD exacerbations and rising to 75% in patients undergoing mechanical ventilation.78–82 HF and COPD exacerbations share precipitating factors, such as respiratory infections, and the main symptoms of both diseases are similar (increased dyspnea), which can complicate diagnosis. The determination of natriuretic peptides is useful for ruling out the presence of HF in patients with COPD exacerbations83 and a positive finding is associated with a worse prognosis in both patients hospitalized for COPD exacerbations and in patients with stable phase COPD.84 (Supplementary Table 3A).

Health-related quality of life is worse in patients with COPD and concomitant HF (Supplementary Table 3A). These patients present a greater risk of mortality and hospital admission85 according to a study of 1264 patients with HF and mild or moderate COPD86 and another study of 7800 patients.87 On the basis of 2 studies in which it was noted that readmission after hospitalization or COPD exacerbation was more frequent in patients with HF,88 the latter being the most frequent reason for readmission,89 and the fact that the presence of HF worsens the short and long-term prognosis of patients hospitalized for COPD exacerbation,79,90 it was concluded that HF worsens the prognosis of COPD patients in terms of both new exacerbations and hospitalizations and mortality (Supplementary Table 3A). It has also been observed that COPD worsens the prognosis of patients hospitalized with HF,91,92 and patients with both comorbidities have a higher risk of death and hospital admissions.

Long-acting bronchodilators, ICS, and LABA-LAMA fixed-dose combinations are safe in patients with HF3,93,94 and do not increase the risk of heart disease.95,96 Some
treatments for HF (cardioselective BBs, such as carvedilol) were also found to be safe in COPD patients, and the use of BB was associated with a reduced risk of mortality and COPD exacerbations. Therefore, the presence of HF does not require a change in the treatment in patients with COPD. (Supplementary Table 3A).

Ischemic Heart Disease
According to a systematic review, the prevalence of ischemic heart disease (IHD) in patients with COPD ranges between 7.1% and 31.3%, depending on the study population, while in studies based on administrative databases, this prevalence has been estimated to be between 22% and 33.6%. Cohort studies conducted in patients hospitalized for COPD exacerbations have shown a prevalence of IHD of between 17% and 22%. The presence of both conditions in conjunction worsens patient prognosis, with COPD patients showing a significantly increased risk of having IHD, a well-recognized cause of mortality in COPD patients. In fact, IHD is one of the most frequent causes of mortality in COPD patients. Several studies have found that quality of life is significantly worse in patients with COPD and concomitant IHD. Moreover, the presence of IHD doubles the risk of hospitalization in patients with COPD, and is associated with an increase in 3-month mortality, and after an exacerbation, the risk of a coronary event in the following weeks is more than doubled. In this regard, we recommend to rule out the possibility of IHD in all patients with COPD (Supplementary Table 3B).

Concerning the need for prescribing appropriate treatments in patients with COPD and IHD, the conclusions and recommendation are in Supplementary Table 3. In the treatment of COPD, no significant differences were found in mortality for combinations of drugs for COPD and IHD, such as salmeterol/fluticasone or vilanterol/fluticasone. The prognosis after an acute coronary event in COPD patients treated with ICS was better than in those who did not receive ICS. The combination of ICS with LABA or LABA + LAMA also gave rise to lower mortality, and LABA and LAMA are safe in patients with COPD and IHD. In the treatment of IHD, statins may have a beneficial effect in COPD, although this was not demonstrated in a clinical trial evaluating the usefulness of statins in reducing COPD exacerbations. The use of statins and angiotensin converting enzyme inhibitors was significantly associated with a decline in 90-day mortality in patients hospitalized for acute exacerbations, BBs decreased mortality in COPD patients after myocardial infarction and the risk of exacerbations in COPD patients with cardiovascular disease. In another retrospective study, continuing treatment with BBs during hospitalization for COPD exacerbations was not associated with an increase in mortality or readmissions at 30 days, while the use of antiplatelet drugs was associated with reduced mortality.

Peripheral Artery Disease
A number of cohort studies have shown a prevalence of peripheral artery disease (PAD) in COPD patients of 8.8%, and between 13% and 16% increasing according to the severity of obstruction. Patients with COPD and PAD have less exercise tolerance and poorer quality of life, and the presence of COPD is associated with a higher readmission rate after PAD is treated with bypass or percutaneous interventions. In patients with stable COPD, a direct relationship was found between an ankle-brachial index of < 1 and an independent increase in 4-year mortality. In hospitalized COPD patients, the presence of PAD was associated with an increase of mortality at 3 months. In view of this evidence, the presence of PAD should be ruled out in COPD patients (Supplementary Table 3C).

Although some studies at the experimental level suggest that treatment with LABA + ICS or LAMA may decrease arterial rigidity (a marker of PAD), in general the treatment of PAD is not affected by COPD treatment. Treatment with statins in patients with PAD and COPD is beneficial and BBs are safe and do not affect quality of life, a finding confirmed in another study focusing on the year after hospitalization. Smoking cessation is also recommended in the clinical practice guidelines for patients with PAD in the lower limbs (Supplementary Table 3C).

Atrial Fibrillation
The prevalence of arrhythmias in patients with stable COPD ranges from 5% to 15%, increasing to up to 20%-30% in patients with more severe COPD. In 2 systematic reviews, it ranged from 5% to 29%, and atrial fibrillation (AF) occurred in 21% and arrhythmia in 27% of patients hospitalized for COPD exacerbation.

The most common arrhythmia in the general population and in patients with COPD is AF, and its presence is inversely associated with FEV1 values. COPD patients are more likely to develop permanent AF and to relapse following cardioversion. COPD exacerbations can cause AF, which in turn can be the cause of COPD exacerbations.
COPD patients with AF have a worse quality of life, and COPD increases the risk of hospitalization for AF by up to 2-fold, while the presence of AF increases mortality in patients hospitalized for COPD exacerbations, thus worsening prognosis. Both dyspnea and hypercapnia and acidosis may predispose to AF. In contrast, no increase in arrhythmias associated with the use of LABA or LAMA has been demonstrated in clinical trials. In contrast, no increase in arrhythmias associated with the use of LABA or LAMA has been demonstrated in clinical trials. In contrast, no increase in arrhythmias associated with inhaled SABA beta adrenergic receptor agonists, and high doses of prednisone have all been associated with an increased risk of AF and arrhythmias-. In contrast, no increase in arrhythmias associated with inhaled SABA beta adrenergic receptor agonists, and high doses of prednisone have all been associated with an increased risk of AF and arrhythmias.-

Several studies have found that treatments for COPD are associated with an increased risk of arrhythmias. The use of short-acting antimuscarinic agents (SAMA), starting treatment with LABA or SAMA in a population study in COPD patients, and oral steroids and theophylline have all been associated with an increased risk of AF and arrhythmias.-

In respect of treatments and to rehabilitation programs or smoking cessation programs, and with a lower exercise tolerance and greater use of healthcare resources.

Anxiety in COPD patients also worsens prognosis, with the consequence of higher health spending, increased frequency of readmissions, and worse self-management of the disease, and is also associated with earlier hospital admission. Moreover, according to a recent meta-analysis, the presence of anxiety increases the likelihood of developing an exacerbation by 31%.

Anxiety also increases mortality rates, emergency department visits, and readmission after exacerbation in the first 30 days after discharge in COPD patients, who have discrepancies in terms of lung function, with respect to the effect of anxiety on them. Some studies have shown a decline in FEV1 while others have found no correlation. Because some of the symptoms of COPD and anxiety are similar (lack of energy, fatigue, sleep disturbances, or less enjoyment of pleasurable activities), it is very important to assess psychological health using questionnaires or scales validated in these patients.

The concomitant use of pharmacological treatments for anxiety and pulmonary rehabilitation programs may have additive therapeutic effects. Physical exercise, as part of pulmonary rehabilitation programs, has a beneficial effect on anxiety associated with COPD. In respect of treatments for anxiety in patients with COPD, the first line of treatment must be non-pharmacological interventions.

In this respect, relaxation techniques showed a mildly positive effect on lung function and levels of anxiety, and a greater effect associated with an improvement in perceived quality of life. In terms of pharmacological interventions, antidepressants alter patients’ perception of some symptoms, such as dyspnea, and improve quality of life. Selective serotonin reuptake inhibitors have reduced anxiety symptoms in the short term (6 months’ follow-up), whereas no significant differences were found with tricyclic antidepressants or azapirones compared to placebo. The UK National Institute for Health and Care Excellence guidelines recommend the use of selective serotonin reuptake inhibitors as first-line treatment in patients with associated anxiety. However, drug-drug interactions must be taken into account, as fluvoxamine reduces the metabolism of theophylline derivatives and interacts with rofumilast, so the use of alternative selective serotonin reuptake inhibitors is recommended. The healthcare professional must be aware of and monitor potential interactions between antidepressants and beta-2 adrenergic agonists or anticholinergic bronchodilators. Theophylline may decrease the anxiolytic effect of benzodiazepines, especially diazepam and alprazolam. The recommendations about the therapy of anxiety in COPD patients are shown in Supplementary Table 4A.
Insomnia

Insomnia can affect up to 70% of COPD patients at some point during their disease, and COPD is a risk factor for insomnia. The incidence of sleep disorders increases with the presence of respiratory symptoms in all age groups over 45 years.

The main consequences of poor sleep quality are reduced quality of life, increased states of anxiety or depression, the uncontrolled and possibly harmful use of hypnotics, and hypoxemia and hypercapnia. The latter two may cause cardiac arrhythmias, pulmonary hypertension, and nocturnal death, especially during acute exacerbations. Insomnia can predict COPD exacerbations, the use of emergency services, and all-cause mortality, which suggests that insomnia may be a significant risk factor for worsening or poor prognosis of COPD.

Asking about the quality of sleep in COPD patients is recommended (Supplementary Table 4B).

Insomnia in COPD patients must be treated (Supplementary Table 4B). In the treatment of insomnia, both a non-pharmacological approach and drug treatment are used, principally with hypnotic drugs and benzodiazepines. Epidemiological studies have suggested that hypnotics increase the risk of respiratory adverse events, such as pneumonia, acute exacerbation, acute respiratory failure, and cardiorespiratory arrest in patients with COPD. Benzodiazepines are currently the hypnotics of first choice in these patients, although they may cause respiratory depression. The anxiolytic effect of benzodiazepines can be reduced with theophylline, and theophylline levels can increase with the use of St. John’s wort, requiring changes in dosing or suspension of the benzodiazepine.

Regarding the interactions between insomnia and COPD, no studies have shown that the treatment of a patient with COPD should differ according to the presence or absence of insomnia, with the exception of possible drug-drug interactions that may occur.

Depression

Depression is a common disorder in COPD patients, with a prevalence of around 25%, which increases with COPD severity, affecting between 50% and 90% of patients with advanced COPD. Thus, COPD increases the risk of depression. The quality of life of patients with COPD and depression is reduced, and exacerbations, admissions and hospital readmissions, emergency room visits, and lengths of hospital stay are higher in these patients. Depression in COPD patients has also been associated with increased mortality and with important clinical consequences, such as greater functional decline, lower exercise tolerance, dyspnea, lower adherence to drug treatment and rehabilitation programs, lower physical activity, and higher healthcare costs in the subsequent 2 years. As a result of this evidence, we recommend that the existence of depression in COPD patients should be ruled out at frequent intervals (Supplementary Table 4C).

The treatment of depression in patients with COPD should be similar to that of the general population, although patients with COPD generally do not receive treatment for depression. Studies that evaluated drug treatments for depression in COPD patients found that SSRIs improve depression, whereas tricyclic antidepressants gave rise to great heterogeneity and high drop-out rates. Treatment with paroxetine improved anxiety and depression in these patients and nortriptyline improved depression, while paroxetine did not worsen respiratory symptoms. Medicare data between 2006 and 2012 reported that patients with COPD and depression who complied with their antidepressant treatment made fewer visits to the emergency room and had fewer hospitalizations.

As for psychological treatment, 3 meta-analyses show that psychological and lifestyle interventions, multicomponent exercise training, and behavioral therapy are associated with a small reduction in depressive symptoms, and that relaxation techniques improved dyspnea and psychological well-being, and also slightly improved respiratory function.

COPD treatment based on respiratory rehabilitation and physical intervention programs also improved depressive symptoms, dyspnea, and quality of life.

There may be drug interactions between treatments for COPD and depression. For example, the combined use of beta-adrenergic agonists and antidepressants could prolong the QT interval and promote the emergence of ventricular arrhythmias. Tricyclic antidepressants may also enhance the cardiovascular adverse effects of beta-adrenergic agonists and, moreover, their anticholinergic effect added to that of bronchodilators (such as ipratropium, tiotropium) can lead to adverse effects. Despite these potential interactions, the combination of antidepressants with anticholinergic or beta-adrenergic bronchodilators is not contraindicated, although recommendations have been made in this regard. For example, a type C interaction has been observed between beta-adrenergic bronchodilators and monoamine oxidase inhibitors (MAOIs) and tricyclic...
antidepressants, so close monitoring of these patients is recommended. The interaction between roflumilast and fluvoxamine is also type C, while a type D interaction has been reported between roflumilast, theophylline, fluvoxamine and St. John’s wort (the combination of these drugs is not recommended and treatment should be modified).

Cognitive Impairment
COPD patients often present cognitive dysfunction; in fact, they are twice as likely to develop cognitive impairment. A systematic review estimated a prevalence of cognitive impairment of 2%-20% in COPD patients. Exacerbations and chronic hypoxemia and hypercapnia in patients with COPD and obstructive sleep apnea syndrome are associated with a greater cognitive impairment. Cognitive impairment is associated with longer hospital stays among patients hospitalized for acute COPD exacerbation and an increased risk of hospital admission. Patients with COPD and dementia have also shown an increased risk of death at 3 years, and cognitive impairment has been associated independently with mortality at 32 months. In another study, the presence of dementia was a predictor of 3-month mortality in patients hospitalized for COPD exacerbation. Looking for and ruling out the existence of cognitive impairment is recommended in COPD patients (Supplementary Table 4D).

With regard to the treatment of patients with COPD and cognitive impairment, we have formulated several recommendations (Supplementary Table 4D), taking into account the following data. Chronic oxygen therapy in COPD patients with hypoxemia has been associated with a decreased risk of cognitive impairment, and patients who followed pulmonary rehabilitation programs showed improved cognitive function in visual attention, verbal memory and visual-spatial functions and, in patients awaiting lung transplantation, an improved mental summary component of SF-36. In the treatment of cognitive impairment, acetylcholinesterase inhibitors were not associated with more emergency department visits, more hospitalizations, or more exacerbations in patients with COPD and dementia. Regarding the possible drug interactions, since anticholinergics counteract the therapeutic effect of central acetylcholinesterase inhibitors used in the treatment of dementia, the protocol of the Spanish Society of Internal Medicine on diagnostic and therapeutic management of comorbidities in COPD recommend that the therapeutic effect of both groups is monitored during concomitant use.

Other Comorbidities
Pain
The prevalence of pain in COPD patients is between 45% and 60% and reaches 70% in advanced stages of the disease, although its incidence is underdiagnosed in these patients. Despite its importance, few clinical trials or meta-analysis have focused on pain associated with COPD and management is barely mentioned in the national and international COPD guidelines. Pain is up to 2.6 times more common in COPD patients than in patients with other chronic diseases.

The presence of pain does not alter lung function in COPD patients, but it is associated with increased dyspnea, worse quality of life, insomnia, fatigue, anxiety, depression, and a poor nutritional status. Pain has not been clearly associated with age, sex, or smoking status. No studies have evaluated pain and COPD disease course in terms of exacerbations, hospital admissions, and survival. For a proper evaluation of the intensity of pain associated with COPD and response to different analgesics, pain quantification scales, such as the Brief Pain Inventory, the McGill Pain Questionnaire, or the Visual Analogue Scale (VAS) are useful. Patients with COPD and pain tend to score high in these scales. Thus, Lohne et al found that 38% of patients with severe COPD score over 6 in a numerical scale of 1 to 10 (Supplementary Table 5A). No evidence is available on the influence of COPD treatment on the treatment of pain, although analgesics are widely consumed by patients with COPD, and used more than by patients without COPD. Neither opioids at appropriate doses nor non-steroidal anti-inflammatory drugs confer a higher risk of respiratory depression in COPD patients, while NSAIDs induce less drowsiness than opioids. The coadjuvant use of tricyclic antidepressants in the treatment of pain should be closely monitored in patients who use beta-2 agonists.

Concerning the interactions between COPD and pain, COPD patients with pain may develop worsening dyspnea, with increased use of bronchodilator medication. Patients following pulmonary rehabilitation programs showed no improvement in pain. Supplementary Table 5A presents the recommendation about treatment of patients with COPD and pain.

Anemia
The prevalence of anemia in patients with COPD was estimated at between 7.5% and 34% in a systematic review, rising to 43.9% in other studies. Being chronic anemia and iron-deficiency anemia the most common in these
patients.\textsuperscript{242} Anemia is more common during exacerbations. A systematic review\textsuperscript{243} found that the presence of anemia in patients with COPD leads to a reduction in quality of life, and a greater number of hospitalizations and readmissions. These findings have been corroborated in studies on administrative databases, in which more exacerbations, hospitalizations, pneumonia, and admissions in intensive care units were observed.\textsuperscript{244,245} Survival of patients with COPD and anemia during hospital admissions is lower,\textsuperscript{241,243,245-249} with a mortality rate twice that of patients without anemia.\textsuperscript{245} In addition, the presence of anemia in COPD is associated with a lower exercise tolerance,\textsuperscript{243} greater dyspnea,\textsuperscript{246} higher C-reactive protein values,\textsuperscript{241} and greater use of healthcare resources.\textsuperscript{243} It is also a risk factor for home oxygen therapy in these patients,\textsuperscript{250} (Supplementary Table 5B). Anemia is a modifiable condition and correction of anemia in chronic diseases other than the COPD has been associated with improved health. No clinical trials are currently available on the treatment of anemia in patients with COPD, but it has been observed in case studies that blood transfusion helped in weaning from mechanical ventilation\textsuperscript{251} and improved both the minute ventilation and work of breathing.\textsuperscript{24} Treatment with intravenous iron and erythropoiesis-stimulating agents improved hemoglobin and dyspnea.\textsuperscript{239} In patients with COPD, the etiological treatment of anemia is recommended (Supplementary Table 5B).

**Osteoporosis**

The prevalence of osteoporosis in patients with COPD ranges between 9\% and 69\%, depending on the study,\textsuperscript{252} being higher in women\textsuperscript{253,254} and 2 to 5 times higher than in the general population.\textsuperscript{252} Osteoporosis is underdiagnosed and undertreated in COPD patients\textsuperscript{255} and has been associated with a lower quality of life.\textsuperscript{256,257} Osteoporosis appears to be a risk factor for COPD and vice versa. In several studies, osteoporosis, lower bone density, and vitamin D deficiency in COPD patients were associated with more acute exacerbations and hospitalizations.\textsuperscript{258,259} Vertebral fracture, lower bone density, osteoporosis, and vitamin D deficiency have also been associated with more hospitalizations.\textsuperscript{258-260} The number of exacerbations has been associated with an increased risk of osteoporosis\textsuperscript{261} and a greater decrease in bone mass.\textsuperscript{262} The degree of obstruction is also associated with an increased risk of bone fractures.\textsuperscript{263} With regard to survival, vertebral fracture in patients with COPD has been associated with higher 2-year mortality.\textsuperscript{260} Each vertebral fracture also reduces forced vital capacity by 9\%.\textsuperscript{263} A systematic review of rehabilitation programs in patients with COPD and osteoporosis found that exercise tolerance improved to a lesser extent than that of patients with other comorbidities.\textsuperscript{264} The existence of osteoporosis should be ruled out in COPD patients. We recommended to check the lateral chest X-ray to find vertebral fractures (Supplementary Table 5C).

No specific treatments are available for osteoporosis in COPD patients, but corsets can be used for the treatment of unstable vertebral fractures. Systemic corticosteroids, used for the treatment of COPD exacerbations, increase the risk of osteoporosis,\textsuperscript{265} and their use has been associated with a higher incidence of fractures.\textsuperscript{265} This is also true of ICS,\textsuperscript{266} for which the association is dose-dependent.\textsuperscript{267} Lung volume reduction surgery\textsuperscript{268} led to an improvement in bone density in 40 patients with emphysema,\textsuperscript{268} and pulmonary rehabilitation programs have been shown to improve exercise tolerance in patients with COPD and osteoporosis.\textsuperscript{264} Bisphosphonates were useful for the treatment of corticosteroid-induced osteoporosis.\textsuperscript{269} Patients with COPD and osteoporosis should be referred for rehabilitation (Supplementary Table 5C).

The potential drug-drug interactions between treatments are not of particular importance, and only steroids show a type C interaction (it is recommended that patients receiving denosumab are closely monitored).\textsuperscript{4}

**Gastroesophageal Reflux Disease**

The prevalence of gastroesophageal reflux disease (GERD) in patients with COPD in Spain has been estimated at 28\%-62\%,\textsuperscript{270-273} higher than in the general population. The severity of GERD symptoms increases with the severity of COPD,\textsuperscript{274,275} and COPD patients diagnosed with GERD have poorer lung function.\textsuperscript{276} The presence of reflux symptoms in COPD patients is related with more frequent and more severe exacerbations.\textsuperscript{277-279} The presence of GERD, then, is an independent risk factor for exacerbations\textsuperscript{276} and is associated with a worse quality of life.\textsuperscript{280-282} and may result in a COPD patient with an “infrequent exacerbator” phenotype developing a “frequent exacerbator” phenotype.\textsuperscript{275} Pulmonary hyperinflation and dyspnea are risk factors associated with the incidence of symptoms of GERD.\textsuperscript{283} The influence of GERD on mortality in COPD is not presently known.\textsuperscript{271,272,276,284} Supplementary Table 5D, shows the conclusions and recommendations referring to the treatment of patients with COPD and. Beta agonists and theophylline, used in the treatment of COPD, can produce reflux symptoms\textsuperscript{285} while tiotropium may reduce the symptoms of GERD.\textsuperscript{284,286} Proton pump inhibitors are the most effective
drugs in GERD and reduce chronic cough in these patients. It has not been demonstrated that high-dose omeprazole improves the degree of pulmonary obstruction or bronchial hyperresponsiveness. Oral lansoprazole has been effective in preventing exacerbations by inhibiting gastric secretion, reducing reflux, and decreasing levels of inflammatory markers in sputum.

Thromboembolic Disease
In Spain, the estimated prevalence of venous thromboembolism in hospitalized patients with COPD is between 8% and 25%, and the incidence of deep venous thrombosis (DVT) is 10%-12%. COPD patients are more likely to develop a venous thromboembolic event [DVT, pulmonary thromboembolism (PTE)], both during exacerbations and in stable phase disease. Clinical manifestations in patients with COPD and thromboembolic disease may be subtle and diagnosis is often delayed, while symptoms of PTE can be confused with a COPD exacerbation. With regard to the influence of thromboembolic disease on quality of life, data from studies vary widely, and in the course of COPD, the presence of DVT in patients with COPD exacerbation results in longer hospital stays, increased risk of PTE, a greater number of intensive care unit admissions, and a greater need for mechanical ventilation and placement of filters in the inferior vena cava. (Supplementary Table 5E). Frequently PTE is the first presentation of thromboembolic disease in COPD patients, and is associated with higher mortality, more frequent hemorrhage, and more recurrence of thrombosis within 3 months.

No evidence is available on the influence of COPD treatment on patients with thromboembolic disease. COPD patients present a greater number of major bleeds, so other therapies such as temporary inferior vena cava filters have been used. In cases of spontaneous VTE, no significant differences were observed in the duration of anticoagulation therapy between patients with or without COPD. Treatment with low molecular weight heparins during acute COPD exacerbations has proved useful in the prevention of DVT: nadroparine prophylaxis in patients with acute COPD exacerbations reduced the incidence of DVT. The Supplementary Table 5E presents the recommendations about prophylaxis and treatment of venous thromboembolic disease in COPD patients.

Chronic Kidney Disease
The prevalence of chronic kidney disease (CKD) in patients with COPD ranges between 6.5% and 26.2%. Moderate CKD has been detected in 6.5% of the COPD population in Spain and 22% of patients with multiple pathologies associated with COPD. Frequently CKD is an unknown comorbidity. The recommendation is to estimate the glomerular filtration rate (CKD-EPI or MDRD equations can be used) in COPD patients (Supplementary Table 5F). CKD is more common in COPD patients with serious lung function impairment and systemic inflammation, and the risk increases significantly when obstructive sleep apnea syndrome occurs in COPD. No studies have yet evaluated the impact of CKD on quality of life in COPD patients and patient progress. With regard to survival, CKD is an adverse prognostic factor related to short-term mortality in patients with COPD, and moderate and severe COPD associated with CKD and acute CKD correlated with an increase in mortality, a finding corroborated in another longitudinal cohort study.

In respect of to the appropriate treatment of patients with COPD and CKD, there is no evidence that COPD treatments influence the treatment of CKD, nor that this comorbidity requires a change in COPD treatment, so it is advisable to follow clinical practice guideline recommendations. (Supplementary Table 5F).

Lung Cancer
The prevalence of COPD in patients with lung cancer (LC) is between 50% and 64%. Moreover, 20%-25% of patients with COPD develop LC, primarily patients with mild or moderate airflow obstruction. According to other data, LC develops in around 3.8%-8.0% of COPD patients.

Ample evidence is available to demonstrate the association between COPD and LC, the common etiologic factor of which is smoking. Also emphysema and airflow limitation are risk factors for LC development. COPD is also an independent risk factor in the development of LC. No studies have assessed the impact of LC on the quality of life of patients with COPD nor have any studies assessed the course of COPD in patients with LC. With regard to survival, various studies show that LC is one of the leading causes of mortality in COPD patients with mild-to-moderate obstruction and that the presence of COPD adversely affects the prognosis of the patient with LC.

There is no evidence that the presence of LC requires a change of treatment in patients with COPD and vice versa. It has been suggested that, due to their anti-inflammatory...
properties, ICS have a possible protective effect on the development of LC, and high doses of these drugs reduce the LC risk. The treatment of LC requires a multidisciplinary approach with additional tests, since the decision to perform resection surgery is more complex due to worse lung function. No drug-drug interactions have been described between treatments for COPD and LC (Supplementary Table 5G). In Supplementary Table 6 we present the recommendations in divergence after the Delphi rounds.

**Conclusions**

In summary, this document presents conclusions and recommendations on the consequences of various comorbidities in COPD patients and the treatment of these patients, proposed by the recommendations preparation group and validated by a group of experts after 2 Delphi rounds. Consensus was reached (agreement > 80%) for a total of 73 recommendations and 81 conclusions that are intended to be useful in the management of patients with COPD and comorbidities.

**Acknowledgments**

The authors would like to thank Heather Hamilton, specialized biomedical translator, for her translation of the manuscript into English. The authors would like to thank Boehringer Ingelheim for their continued and constant support for this project, and GOC Networking team for their support and collaboration in the development of this document and for editorial assistance. The authors would also like to thank the 23 experts who participated in the Delphi process for the validation of the conclusions and recommendations prepared by the RPG: Dr. Fernando Javier Sánchez Lora (Hospital Virgen de la Victoria, Malaga); Dr. Jesús Castiella Herrero (Hospital Fundación de Calahorra, La Rioja); Dr. Joaquín Antón Martínez (Hospital San Pedro Alcántara, Cáceres); Dr. Manuel Jesús Menduíña Guillén (Hospital Clínico San Cecilio, Granada); Dr. José Portillo Sánchez (Hospital General De Ciudad Real, Ciudad Real); Dr. Ramón Boixeda i Viu (Hospital De Mataró, Barcelona); Dr. Xoel Pena Pérez (Hospital Sant Joan De Deu, Barcelona); Dr. Elena Zubillaga Azpiroz (Hospital De Zumárraga, Guipúzcoa); Dr. Maria del Carmen Romero Pérez (Hospital Severo Ochoa, Madrid); Dr. María Gómez Antúnez (Hospital Gregorio Marañón, Madrid); Dr. Mercedes Racionero Moreno (Hospital Virgen De La Luz, Cuenca); Dr. Núria Galofré Álvaro (Hospital Municipal de Badalona, Barcelona); Dr. Olga H. Torres Bonafonte (Hospital Santa Creu i Sant Pau, Barcelona); Dr. Meritxell Salvadó Soro (Hospital de Mollet, Barcelona); Dr. Jorge Cabello Carro (Hospital Clínico San Carlos, Madrid); Dr. Robert Hurtado García (Hospital de la Vega Baja de Orihuela, Alicante); Dr. Lorena Montero Rivas (Hospital Infanta Margarita De Cabra, Córdoba); Dr. María Luz Calero Bernal (Hospital de San Juan de Dios de Bormujos, Seville); Dr. Pilar Martínez Heras (Hospital Miguel Servet, Zaragoza); Dr. José Luis Fernández Reyes (Complejo Hospitalario de Jaén, Jaén); Dr. María Belén Alonso Ortiz (Hospital Juan Negrín, Las Palmas de Gran Canaria); Dr. Carlos Trescoli* (Hospital de la Ribera, Valencia), and Dr. Enrique Peral Gutiérrez de Ceballos* (Hospital Virgen de la Macarena, Seville) *These panelists only participated in the first of the 2 Delphi rounds.

**Author Contributions**

All the authors of this document made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

**Funding**

This work was supported by a grant from Boehringer Ingelheim.

**Disclosure**

Jesús Recio Iglesias has received speaker or consulting fees from Boehringer Ingelheim, Chiesi, Ferrer and Novartis unrelated to this manuscript. Jesús Díez Manglano has received speaker or consulting fees from Bayer, Bristol-Myers-Squibb, Chiesi, and Novartis unrelated to this manuscript. Francisco López García has received speaker or consulting fees from Boehringer Ingelheim, Chiesi, GSK and Novartis unrelated to this manuscript. José Antonio Díaz Peromingo has received speaker or clinical trials fees from Boehringer, Chiesi, Bayer, Bristol, Novartis, Faes, GSK and Sanofi. Pere Almagro Mena has received grants from Astra Zeneca and SEPAR, personal fees from Chiesi, Boehringer Ingelheim and GSK and travel support from Rovi and Esteve, outside the submitted work. Jose Manuel Varela Aguilar has received speaker or consulting fees from Astra Zeneca, Boehringer Ingelheim, Chiesi, GSK, Menarini, Novartis, Novo Nordisk and RoVi. The authors report no other conflicts of interest in this work.
Referencias

1. Organización Mundial de la Salud (OMS). Descriptivo: trastornos crónico obstructivos pulmonar. 2016; enero. Available from: http://www.who.int/mediacentre/factsheets/fs315/en/. Accessed January 2017.

2. Miravitlles M, Soriano JB, García-Rio F, et al. Prevalencia de COPD en España: impacto de un diagnóstico COPD en la calidad de vida y la calidad de vida de la vida diaria. Thorax. 2009;64(10):863–868. doi:10.1136/thx.2009.115725

3. Grupo de Trabajo de GesEPOC. Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) – guía Española de la EPOC (GesEPOC). Versión 2017 [Clinical Practice Guidelines for the Diagnosis and Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD) – Spanish Guideline for COPD (GesEPOC). 2017 version]. Arch Bronconeumol. 2017;53(Suppl 1):2–64. Spanish.

4. Díez-Manglano J, López-García F. Protocolos: manejo Diagnóstico y Terapéutico de las Comorbididades en la EPOC [Protocolos: Diagnostico and Therapeutic management of Comorbidities in COPD]. Sociedad Española de Medicina Interna (SEMI) y Elsevier SL. 2014;1:259. Spanish.

5. Global Initiative for Chronic Obstructive Lung Disease (GOLD). From the global strategy for the diagnosis, management and prevention of COPD. 2017. Available from: http://goldcopd.org. Accessed March 16, 2020.

6. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28(6):1245–1257. doi:10.1183/09031936.00133805

7. Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:871–888. doi:10.2147/COPD.s36409

8. Brook R. The RAND/UCLA Appropriateness Method. Rockville, MD: AHCP/RP Pub; 1994.

9. Scottish Intercollegiate Guidelines Network. A Guideline Developers’ Handbook (Publication Nº 50). Edinburgh: SIGN; 2001. Available en: http://www.sign.ac.uk/guidelines/fulltext/50/index.html. Accessed March 16, 2020.

10. Oxford Centre for Evidence-Based Medicine. Levels of Evidence Document. (Consultado Enero 2017). 2011 Disponible en: http:// www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf. Accessed March 16, 2020.

11. Schols AM, Buurman WA, Staal van den Brekel AJ, Dentmener MA, Wouters EF. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996;51(8):819–824. doi:10.1136/thx.51.8.819

12. Almagro Mena P, Rodríguez Carballeira M. Afectación extrapulmonar en la EPOC: ¿Qué es relevante y cómo debemos evaluarla [Extrapulmonary involvement in COPD: what is relevant and how should we evaluate it?] Med Clin (Barc). 2011;18–23. Spanish.

13. García-Rio F, Soriano JB, Miravitlles M, et al. Impact of obesity on the clinical profile of a population-based sample with chronic obstructive pulmonary disease. PLoS One. 2014;9(8):e105220. doi:10.1371/journal.pone.0105220

14. Steuten LM, Creutzberg EC, Vrijhoef HJ, Wouters EF. COPD as a multicomponent disease: inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care. Prim Care Respir J. 2006;15(2):84–91. doi:10.1016/j.pcrj.2005.09.001

15. Fransen FM, O’Donnell DE, Goossens GH, Blaak EE, Schols AM. Obesity and the lung: 5. Obesity and COPD. Thorax. 2008;63(12):1110–1117. doi:10.1136/thx.2007.086827

16. Cecere LM, Littman AJ, Slatore CG, et al. Obesity and COPD-associated symptoms, health-related quality of life, and medication use. COPD. 2011;8(4):275–284. doi:10.3109/15412555.2011.586660

17. Vozoris NT, O’Donnell DE. Prevalence, risk factors, activity limitation and health care utilization of an obese, population-based sample with chronic obstructive pulmonary disease. Can Respir J. 2012;19(3):e18–24. doi:10.1155/2012/732618

18. Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420–426. doi:10.1002/issn.1529-0131

19. Yuan L, Dai X, Yang M, Cai Q, Shao N. Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2016;11:1477–1483. doi:10.2147/COPD.S106370

20. Sava F, Laviolette L, Bernard S, Breton MJ, Bourbeau J, Maltais F. The impact of obesity on walking and cycling performance and response to pulmonary rehabilitation in COPD. BMC Pulm Med. 2010;10(1):55. doi:10.1186/1471-2466-10-55

21. Ramachandran K, McCusker C, Connors M, Zuwallack R, Lahiri B. The influence of obesity on pulmonary rehabilitation outcomes in patients with COPD. Chron Respir Dis. 2008;5(4):205–209. doi:10.1177/1479972308096711

22. Sabino PG, Silva BM, Brunetto AF. Nutritional status is related to fat-free mass, exercise capacity and inspiratory strength in severe chronic obstructive pulmonary disease patients. Clinics (Sao Paulo). 2010;65(6):599–605. doi:10.1590/S1807-59222010000600007

23. Farsang C, Kiss I, Tykarski A, Narkiewicz K. Treatment of hypertension in patients with chronic pulmonary disease (COPD). Eur Soc Hypertension Sci Newsletter. 2016;17:62.

24. Schonhofer B, Wenzel M, Geibel M, Kohler D. Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. Crit Care Med. 1998;26(11):1824–1828. doi:10.1097/00003246-199811000-00022

25. Miller J, Edwards LD, Agusti A, et al. Comorbidities, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9):1376–1384. doi:10.1016/j.rmed.2013.05.001

26. Schnabel E, Nowak D, Brache S, Wichmann HE, Heinrich J. Association between lung function, hypertension and blood pressure medication. Respir Med. 2011;105(5):727–733. doi:10.1016/ j.rmed.2010.12.023

27. Wakabayashi K, Gonzalez MA, Delhaye C, et al. Impact of chronic obstructive pulmonary disease on acute-phase outcome of myocardial infarction. Am J Cardiol. 2010;106(3):305–309. doi:10.1016/j.amjcard.2010.03.026

28. Worth H, Chung KF, Felser JM, Hu H, Rueegg P. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011;105(4):571–579. doi:10.1016/j.rmed.2010.11.027

29. Wise RA, Anzuto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491–1501. doi:10.1056/NEJMoa1303342

30. White WB, Cooke GE, Kowey PR, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest. 2012;144(3):758–765. doi:10.1378/chest.12-2332

31. Di Daniele N. Therapeutic approaches of uncomplicated arterial hypertension in patients with COPD. Palm Pharmacol Ther. 2015;35:1–7. doi:10.1016/j.pupt.2015.09.004

32. Mancini GB, Efthimiou M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554–2560. doi:10.1016/j.jacc.2006.04.039
33. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;4:CD003566.

34. Cazzola M, Noschese P, D’Amato G, Matera MG. The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction. Chest. 2002;121(1):230–241. doi:10.1378/chest.121.1.230

35. Cazzola M, Noschese P, D’Amato M, D’Amato G. Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma. Chest. 2006;128(5):1322–1326. doi:10.1378/chest.118.5.1322

36. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. 2008;63(4):301–305. doi:10.1136/thx.2007.081893

37. Rutten FH, Zuithoff NP, Hak E, Grobbe DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170(10):880–887. doi:10.1001/archinternmed.2010.1112

38. Hill NS. Fluid and electrolyte considerations in diuretic therapy for hypertensive patients with chronic obstructive pulmonary disease. Arch Intern Med. 1986;146(1):129–133. doi:10.1001/archinte.1986.00360130159022

39. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–969. doi:10.1183/09031936.0012408

40. Almagro P, Lopez F, Cabrera FJ, et al. Comorbilidades en pacientes hospitalizados por enfermedad pulmonar obstructiva crónica. Análisis comparativo de los estudios ECCO y ESMI [Comorbilidades en hospitalizados pacientes con crónico obstructiva pulmonar enfermedad]. Comparative analysis of the ECCO and ESMI studies. Rev Clin Exp. 2012;212(6):281–286. doi:10.1016/j.rec.2012.02.014. Spanish.

41. Ehrlich SF, Quesenberry CP Jr., Van Den Eeden SK, Shan J, Ferrara A. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care. 2010;33(1):55–60. doi:10.2337/dc09-0880

42. Wacker ME, Hunger M, Karrasch S, et al. Health-related quality of life and chronic obstructive pulmonary disease in early stages - longitudinal results from the population-based KORA cohort in a working age population. BMC Pulm Med. 2014;14:134. doi:10.1186/1471-2466-14-134

43. Janson C, Marks G, Buist S, et al. The impact of COPD on health status: findings from the BOLD study. Eur Respir J. 2013;42(6):1472–1483. doi:10.1183/09031936.00153712

44. Lopez Varela MV, Montes de Oca M, Halbert R, et al. Cardioselective beta-blockers in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):916–921. doi:10.1136/thx.2005.050129

45. Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab. 2011;96(6):1789–1796. doi:10.1210/jc.2010-2729

46. Putcha N, Puhan MA, Hansel NN, Drummond MB, Boyd CM. Hyperglycaemia as a predictor of death in patients with moderate COPD. Thorax. 2008;64(10):857–862. doi:10.1136/thx.2008.096989

47. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009;34(2):380–386. doi:10.1183/09031936.00144208

48. Cazzola M, Bettoncelli G, Sessa E, Crisci F, Biscione G. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 2010;80(2):112–119. doi:10.1159/000281880

49. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001–1006. doi:10.1016/j.amjmed.2010.06.019

50. O’Byrne PM, Rennard S, Gerstein H, et al. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respir Med. 2012;106(11):1487–1493. doi:10.1016/j.rmed.2012.07.011

51. Garcia-Olmos L, Alberquilla A, Ayala V, et al. Comorbidity in patients with chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a cross-sectional study. BMC Pulm Med. 2013;13:11. doi:10.1186/1471-2296-14-11

52. de Lucas-ramos P, Izquierdo-Alonso JL, Rodriguez-Gonzalez Moro JM, et al. [Cardiovascular risk factors in chronic obstructive pulmonary disease: results of the ARCE study]. Arch Bronconeumol. 2008;44(5):233–238. doi:10.1159/0001319937

53. de Lucas-ramos P, Izquierdo-Alonso JL, Rodriguez-Gonzalez Moro JM, Frances JF, Lozano PV, Bellon-Cano JM. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). Int J Chron Obstruct Pulmon Dis. 2012;7:679–686. doi:10.2147/COPD.S36222

54. Basili S, Ferroni P, Viéri M, et al. Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. Atherosclerosis. 1999;147(2):249–252. doi:10.1016/S0021-9150(99)00192-6

55. Ettinger WH, Klinefelter HF, Kwiterovitch PO. Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis. 1987;63(2–3):167–172. doi:10.1016/0021-9150(87)90117-1

56. Basili S, Ferroni P, Viéri M, et al. Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. Atherosclerosis. 1999;147(2):249–252. doi:10.1016/S0021-9150(99)00192-6

57. Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab. 2011;96(6):1789–1796. doi:10.1210/jc.2010-2729

58. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009;34(2):380–386. doi:10.1183/09031936.00144208

59. de Lucas-ramos P, Izquierdo-Alonso JL, Rodriguez-Gonzalez Moro JM, Frances JF, Lozano PV, Bellon-Cano JM. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). Int J Chron Obstruct Pulmon Dis. 2012;7:679–686. doi:10.2147/COPD.S36222

60. Basili S, Ferroni P, Viéri M, et al. Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. Atherosclerosis. 1999;147(2):249–252. doi:10.1016/S0021-9150(99)00192-6

61. Ettinger WH, Klinefelter HF, Kwiterovitch PO. Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis. 1987;63(2–3):167–172. doi:10.1016/0021-9150(87)90117-1

62. Basili S, Ferroni P, Viéri M, et al. Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. Atherosclerosis. 1999;147(2):249–252. doi:10.1016/S0021-9150(99)00192-6

63. Ettinger WH, Klinefelter HF, Kwiterovitch PO. Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis. 1987;63(2–3):167–172. doi:10.1016/0021-9150(87)90117-1

64. Hooper PL, Woo W, Visconti L, Pathak DR. Terbutaline raises high-density-lipoprotein-cholesterol levels. N Engl J Med. 1991;325(14):1455–1457. doi:10.1056/NEJM19911210102406
65. de Miguel Diez J, Chancafe Morgan J, Jimenez Garcia R. The association between COPD and heart failure risk: a review. *Int J Chron Obstruct Pulmon Dis*. 2013;8:305–312. doi:10.2147/COPD.S31226

66. Tsiligianni IG, Kosmas E, Van der Molen T, Tanaknix N. Managing comorbidity in COPD: a difficult task. *Curr Drug Targets*. 2013;14(2):158–176. doi:10.2174/13894501134000004

67. Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. *Am J Cardiol*. 2008;101(4):530–535. doi:10.1016/j.amjcard.2007.09.012

68. Criner GJ, Comnett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. *N Engl J Med*. 2014;370(23):2201–2210. doi:10.1056/NEJMoa1403086

69. Chughtai B, Kuriachan S, Magazine R, et al. A prospective, randomized study: evaluation of the effect of rosuvastatin in patients with chronic obstructive pulmonary disease and pulmonary hypertension. *Indian J Pharmacol*. 2016;48(5):503–508. doi:10.4103/0253-7613.190721

70. Ingebrigtsen TS, Marott JL, Nordestgaard BG, Lange P, Hallas J, Vestbo J. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. *Thorax*. 2015;70(1):33–40. doi:10.1136/thoraxjnl-2014-205795

71. Huang CC, Chan WL, Chen YC, et al. Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study in Taiwan. *Clin Ther*. 2011;33(10):1365–1370. doi:10.1016/j.clinthera.2011.08.010

72. Ajmera M, Shen C, Sambamourthi U. Association between statin medications and COPD-specific outcomes: a real-world observational study. * Drugs Real World Outcomes*. 2017;4(1):9–19. doi:10.1007/s40801-016-0101-6

73. Lahousse L, Loth DW, Joos GF, et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. *Pulm Pharmacol Ther*. 2013;26(2):212–217. doi:10.1016/j.ppt.2012.10.008

74. Raymakers AJN, Sadatsafavi M, Sin DD, De Vera MA, Lynd LD. The impact of statin drug use on all-cause mortality in patients with COPD: a population-based cohort study. *Chest*. 2017;152(3):486–493. doi:10.1016/j.chest.2017.02.002

75. Citgez E, van der Palen J, Koehorst-Ter Huurne K, Movig K, van der Valk P, Brusse-Keizer M. Statins and morbidty and mortality in COPD in the COMIC study: a prospective COPD cohort study. *BMJ Open Respir Res*. 2016;3(1):e000142. doi:10.1136/bmjresp-2016-000142

76. Zhang W, Zhang Y, Li CW, Jones P, Wang C, Fan Y. Effect of statins on COPD: a meta-analysis of randomized controlled trials. *Chest*. 2017;152(6):1126–1137. doi:10.1016/j.chest.2017.04.021

77. Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. *Transl Res*. 2013;162(4):237–251. doi:10.1016/j.trsl.2013.05.001

78. Almagro P, Lopez Garcia F, Cabrera FJ, et al. Comorbidity and gender-related differences in patients hospitalized for COPD. The ECCO study. *Respir Med*. 2010;104(2):253–259. doi:10.1016/j.rmed.2009.09.019

79. Almagro P, Cabrera FJ, Diez J, et al. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de medicina interna (ESMI) study. *Chest*. 2012;142(5):1126–1133. doi:10.1378/chest.11-2413

80. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). *Am Heart J*. 2007;153(6):1021–1028. doi:10.1016/j.ahj.2007.03.012

81. Mentz RJ, Fiuzaat M, Wojdyla DM, et al. Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF. *Eur J Heart Fail*. 2012;14(4):395–403. doi:10.1093/eurjhf/hfs009

82. Matamis D, Tsagourias M, Papathanasiou A, et al. Targeting occult heart failure in intensive care unit patients with acute chronic obstructive pulmonary disease exacerbation: effect on outcome and quality of life. *J Crit Care*. 2014;29(2):313.e317–314. doi:10.1016/j.jcrc.2013.11.011

83. Suzuki T, Lyon A, Saggar R, et al. Editor’s choice-biomarkers of acute cardiovascular and pulmonary diseases. *Eur Heart J Acute Cardiovasc Care*. 2016;5(5):416–433. doi:10.1177/2048871616652309

84. Pavasini R, Tavazzi G, Biscaglia S, et al. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis. *Chron Respir Dis*. 2017;14(2):117–126. doi:10.1177/1479972316674393

85. Cavaillies A, Brinchhult-Rabin G, Dixmier A, et al. Comorbidities of COPD. *Eur Respir Rev*. 2013;22(130):454–473. doi:10.1183/09059180.0008612

86. Lee H, Jhun BW, Cho J, et al. Different impacts of respiratory symptoms and comorbidities on COPD-specific health-related quality of life by COPD severity. *Int J Chron Obstruct Pulm Dis*. 2017;12:3301–3310. doi:10.2147/COPD

87. Henoch I, Strang S, Lofdahl CG, Ekberg-Jansson A. Health-related quality of life in a nationwide cohort of patients with COPD related to other characteristics. *Eur Clin Respir J*. 2016;3(1):31459. doi:10.3402/ecrj.v3.31459

88. Jacobs DM, Noyes K, Zhao J, et al. Early hospital readmissions after an acute exacerbation of chronic obstructive pulmonary disease in the nationwide readmissions database. *Ann Am Thorac Soc*. 2018;15(7):837–845. doi:10.1513/AnnalsATS.201712-9130C

89. Shah T, Charpek MM, Coca Perraillon M, Konetzka RT. Understanding why patients with COPD get readmitted: a large national study to delineate the Medicare population for the readmissions penalty expansion. *Chest*. 2015;147(5):1219–1226. doi:10.1378/ chest.14.2181

90. Almagro P, Calbo E, Ochoa de Echaguen A, et al. Mortality after hospitalization for COPD. *Chest*. 2002;121(5):1441–1448. doi:10.1378/chest.121.5.1441

91. Tavazzi L, Swedberg K, Komajda M, et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. *Int J Cardiol*. 2013;170(2):182–188. doi:10.1016/j.ijcard.2013.10.068

92. Canepa M, Straburzynska-Migaj E, Drozdz J, et al. Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. *Eur J Heart Fail*. 2018;20(1):100–110. doi:10.1002/ejhf.964

93. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. *Am J Respir Crit Care Med*. 2017;195(s):557–582. doi:10.1164/rcrn.2017-0218PP

94. Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. *Lancet*. 2016;387(10030):1817–1826. doi:10.1016/S0140-6736(16)30069-1

95. Saps JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA. Risk of cardiovascular and cerebrovascular events in COPD patients treated with long-acting beta2-agonist combined with a long-acting muscarinic or inhaled corticosteroid. *Ann Pharmacother*. 2015;51(11):945–953. doi:10.1177/1060028017719176
96. Rodrigo GJ, Price D, Anzueto A, et al. LABA/LABA neurotoxicity or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulm Dis. 2017;12:907–922. doi: 10.2147/COPD.S126044

97. Roversi S, Fabbrri LM, Sin DD, Hawkins NM, Agusti A. Chronic obstructive pulmonary disease and cardiac diseases. An urgent need for integrated care. Am J Respir Crit Care Med. 2016;194(11):1319–1336. doi:10.1164/rccm.201604-0690SO

98. Lainscak M, Podbregar M, Kovacic D, Rozman J, von Hachling S. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med. 2011;105(Suppl 1):S44–49. doi:10.1016/j.rsm.2011.07.001

99. Coiro S, Girend N, Rossignol P, et al. Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the high-risk myocardial infarction database initiative. Eur J Heart Fail. 2017;19(2):271–279. doi:10.1002/ejhf.647

100. Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One. 2014;9(11):e113048.

101. Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012;12(1):48. doi:10.1186/1471-2466-12-48

102. Miravitles M, Soler-Cataluna JJ, Calle M, et al. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53(6):324–335. doi:10.1016/j.arbes.2017.03.018

103. Putcha N, Drummond MB, Wise RA, Hansel NN. Comorbidities and chronic obstructive pulmonary disease: prevalence, influence on outcomes, and management. Semin Respir Crit Care Med. 2015;36(4):575–591. doi:10.1055/s-0035-1550075

104. Mapel DW, Dedrick D, Davis K. Trends and cardiovascular co-morbidities in COPD patients in the veterans administration medical system, 1991–1999. COPD. 2005;2(1):35–41. doi:10.1081/COPD-200050671

105. Mullerova H, Agusti A, Ereqou S, Mapel DW. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144(4):1163–1178. doi:10.1378/chest.12-2847

106. Mapel D. Insights into COPD comorbidities from the OLIN study and other large databases. COPD. 2011;8(6):397–399. doi:10.3109/15412555.2011.636555

107. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–639. doi:10.1016/S2213-2600(15)00241-6

108. Soriano Ortiz JB, Almagro P, Sauleda Roig J. Causes of mortality in COPD. Arch Bronconeumol. 2009;45(Suppl 4):8–13. doi:10.1016/S0300-2896(09)72857-1

109. Miguel-Diez J, Carrasco-Garrido P, Rejas-Gutierrez J, et al. The influence of heart disease on characteristics, quality of life, use of health resources, and costs of COPD in primary care settings. BMC Cardiovasc Disord. 2010;10(1):8. doi:10.1186/1471-2261-10-8

110. Black-Shinn JL, Kinney GL, Wise AL, et al. Cardiovascular disease is associated with COPD severity and reduced functional status and quality of life. COPD. 2014;11(5):546–551. doi:10.3109/15412555.2014.898029

111. Patel ARC, Donaldson GC, Mackay AJ, Wozniak JA, Hurst JR. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest. 2012;141(4):851–857. doi:10.1378/chest.11-0853

112. Dalal AA, Shah M, Lunacek O, Hanania NA. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. Respir Med. 2011;105(10):1516–1522. doi:10.1016/j.rmed.2011.04.005

113. Patel AR, Kowlessar BS, Donaldson GC, et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(9):1091–1099. doi:10.1164/rccm.201306-1170OC

114. Campo G, Pavasini R, Malagù M, et al. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc Drugs Ther. 2015;29(2):147–157. doi:10.1007/s10557-014-6659-y

115. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. doi:10.1056/NEJMoa063070

116. Contoli M, Campo G, Pavasini R, et al. Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients. Eur J Intern Med. 2018;47:82–86. doi:10.1016/j.ejim.2017.08.016

117. Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901

118. Vestbo J, Fabbrri L, Papi A, et al. Inhaled corticosteroid containing combinations and mortality in COPD. Eur Respir J. 2018;52(6):1801230. doi:10.1183/13993003.01230-2018

119. Xia N, Wang H, Nie X. Inhaled long-acting beta2-agonists do not increase fatal cardiovascular adverse events in COPD: a meta-analysis. PLoS One. 2015;10(9):e0137904. doi:10.1371/journal.pone.0137904

120. Cazzola M, Calzetta L, Matera MG, Muscoli S, Rogliani P, Romeo F. Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. Respir Med. 2015;109(8):1019–1025. doi:10.1016/j.rmed.2015.05.021

121. Mortensen EM, Copeland LA, Pugh MJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10(1):45. doi:10.1186/1465-9921-10-45

122. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between beta-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax. 2012;67(11):977–984. doi:10.1136/thoraxjnl-2012-201945

123. Pavasini R, Biscaglia S, d’Aszenzo F, et al. Antiplatelet treatment reduces all-cause mortality in COPD patients: a systematic review and meta-analysis. COPD. 2016;13(4):509–514. doi:10.3109/15412555.2015.1099620

124. Houwen-Wilke S, Jorres RA, Bals R, et al. Peripheral artery disease and its clinical relevance in patients with chronic obstructive pulmonary disease in the COPD and systemic consequences-comorbidities network study. Am J Respir Crit Care Med. 2017;195(2):189–197. doi:10.1164/rccm.201602-0354OC

125. Aziz F, Lehman EB. Preexisting conditions determine the occurrence of unplanned readmissions after procedures for treatment of peripheral arterial disease. Ann Vasc Surg. 2018;50:60–72. doi:10.1016/j.avsg.2018.01.075

126. Washki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140(2):331–342. doi:10.1378/chest.10-2521

127. Pepin JL, Cockcroft JR, Midwinter D, Sharma S, Rubin DB, Andreas S. Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/ vilanterol with tiotropium. Chest. 2014;146(6):1521–1530. doi:10.1378/chest.13-2859
161. Coventry PA, Bower P, Keyworth C, et al. The effect of complex interventions on depression and anxiety in chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One. 2013;8(4):e60532. doi:10.1371/journal.pone.0060532

162. Abrams TE, Vaughan-Sarrazin M, Van der Weg MW. Acute exacerbations of chronic obstructive pulmonary disease and the effect of existing psychiatric comorbidity on subsequent mortality. Psychosomatics. 2011;52(5):441–449. doi:10.1016/j.psym.2011.03.005

163. Tielens A, Kosmas E, Bratts D, et al. Prevalence of alexithymia and its association with anxiety and depression in a sample of Greek chronic obstructive pulmonary disease (COPD) outpatients. Ann Gen Psychiatry. 2010;9:16. doi:10.1186/1744-859X-9-16

164. Alexopoulos GS, Sirey JA, Raue PJ, Kanellopoulos D, Clark TE, Novitch RS. Outcomes of depressed patients undergoing inpatient pulmonary rehabilitation. Am J Geriatr Psychiatry. 2006;14(5):466–475. doi:10.1097/01.JGP.0000199381.98971.d1

165. Dursunoglu N, Kokturk N, Baha A, et al. Comorbidities and their impact on chronic obstructive pulmonary disease. Tuber Tokars. 2016;64(4):289–298. doi:10.5578/tt.2245

166. National Collaborating Centre for Mental Health. National Institute for Health and Clinical Excellence: guidance. In: Depression: The Treatment and Management of Depression in Adults (Updated Edition). Leicester (UK): British Psychological Society; Copyright (c) The British Psychological Society & The Royal College of Psychiatrists; 2010.2010.

167. Britain G; Excellence NIfC. Anxiety: Management of Anxiety (Panic Disorder, with or Without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care. National Institute for Clinical Excellence; 2004.

168. Volpato E, Banfi P, Rogers SM, Paginini F. Relaxation techniques for people with chronic pulmonary disease: a systematic review and a meta-analysis. Evid Based Complement Alternat Med. 2015;2015:628365. doi:10.1155/2015/628365

169. Yohannes AM, Connolly MJ, Baldwin RC. A feasibility study of antidepressant drug therapy in depressed elderly patients with chronic obstructive pulmonary disease. Int J Geriatr Psychiatry. 2001;16(5):451–454. doi:10.1002/jgs.461

170. Lacasse Y, Beaudoin L, Rousseau L, Maltais F. Randomized trial of paroxetine in end-stage COPD. Monaldi Arch Chest Dis. 2004;61(3):3. doi:10.4081/monaldi.2004.692

171. Eisler N, Harte R, Spiros K, Phillips C, Isaac MT. Effect of treating depression on quality-of-life and exercise tolerance in severe COPD. Cogn. 2005;2(2):233–241. doi:10.1081/COPD-57596

172. Light RW, Merrill EJ, Despars J, Gordon GH, Mutalipassi LR. Docepin treatment of depressed patients with chronic obstructive pulmonary disease. Arch Intern Med. 1986;146(7):1377–1380. doi:10.1001/archinte.1986.00360190155022

173. Borson S, McDonald GJ, Gayle T, Deffebach M, Lakshminarayan S, VanTuien C. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics. 1992;33(2):190–201. doi:10.1016/S0033-1822(92)71995-1

174. Depression in adults: recognition and management | guidance and guidelines | NICE. 2018; Available from: https://www.nice.org.uk/guidance/cg90. Accessed March 16, 2020.

175. Yohannes AM, Alexopoulos GS. Pharmacological treatment of depression in older patients with chronic obstructive pulmonary disease: impact on the course of the disease and health outcomes. Drugs Aging. 2014;31(7):483–492. doi:10.1007/s40266-014-0186-0

176. Price D, Small M, Milligan G, Higgins V, Gil EG, Estruch J. Impact of night-time symptoms in COPD: a real-world study in five European countries. Int J Chron Obstruct Pulmon Dis. 2013;8:595–603. doi:10.2147/COPD.S48570

177. Nunes DM, Mota RM, de Pontes Neto OL, Pereira ED, de Bruin VM, de Bruin PF. Impaired sleep reduces quality of life in chronic obstructive pulmonary disease. Lung. 2009;187(3):159–163. doi:10.1007/s00408-009-9147-5

178. Valipour A, Lavie P, Lothaller H, Mikulic I, Burghuber OC. Sleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary disease. Sleep Med. 2011;12(4):367–372. doi:10.1016/j.sleep.2010.08.017

179. Budhiraja R, Siddiqui TA, Quan SF. Sleep disorders in chronic obstructive pulmonary disease: etiology, impact, and management. J Clin Sleep Med. 2015;11(3):259–270. doi:10.5664/jcsm.4540

180. Dodge R, Cline MG, Quan SF. The natural history of insomnia and its relationship to respiratory symptoms. Arch Intern Med. 1995;155(16):1797–1800. doi:10.1001/archinte.1995.00430160145014

181. Scharf SM, Maimon N, Simon-Tuval T, Bernhard-Scharf BJ, Reuveni H, Tarasiuk A. Sleep quality predicts quality of life in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2010;6:1–12. doi:10.2147/COPD

182. McNicholls WT, Verbraecken J, Marin JM. Sleep disorders in COPD: the forgotten dimension. Eur Respir Rev. 2013;22(129):365–375. doi:10.1183/09031984.0003213

183. Omachi TA, Blane PD, Claman DM, et al. Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med. 2012;13(5):476–483. doi:10.1016/j.sleep.2011.12.007

184. Roth T. Hypnotic use for insomnia management in chronic obstructive pulmonary disease. Sleep Med. 2009;10(1):19–25. doi:10.1016/j.sleep.2008.06.005

185. Chung WS, Lai CY, Lin CL, Kao CH. Adverse respiratory events associated with hypnotics use in patients of chronic obstructive pulmonary disease: a population-based case-control study. Medicine (Baltimore). 2015;94(27):e1110. doi:10.1097/MD.000000000000213

186. Vozoris NT, Fischer HD, Wang X, et al. Benzodiazepine use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Drugs Aging. 2013;30(3):183–192. doi:10.1007/s40266-013-0056-1

187. Vozoris NT, Fischer HD, Wang X, et al. Benzodiazepine use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2014;44(2):332–340. doi:10.1183/09031936.0000814

188. Zhang MW, Ho RC, Cheung MW, Fu E, Mak A. Prevalence of depressive symptoms in patients with chronic obstructive pulmonary disease: a systematic review, meta-analysis and meta-regression. Gen Hosp Psychiatry. 2011;33(3):217–223. doi:10.1016/j.genhosppsych.2011.03.009

189. Huber MB, Wacker ME, Vogelmeier CF, Leidl R. Comorbid influences on generic health-related quality of life in COPD: a systematic review. PLoS One. 2015;10(7):e0132670. doi:10.1371/journal.pone.0132670

190. Omachi TA, Katz PP, Yelin EH, et al. Depression and health-related quality of life in chronic obstructive pulmonary disease. Am J Med. 2009;122(8):778–779.715. doi:10.1016/j.amjmed.2009.01.036

191. Ng TP, Niti M, Fones C, Yap KB, Tan WC. Co-morbid association of depression and COPD: a population-based study. Respir Med. 2010;103(6):895–901. doi:10.1016/j.rmed.2008.12.010

192. Salte K, Tilstedt I, Halling A. Depression is associated with poor prognosis in patients with chronic obstructive pulmonary disease - a systematic review. Dan Med J. 2015;62(10):A5137.

193. Loehrer I, Richter M, Franzen DP, et al. The frequent and underrecognised co-occurrence of acute exacerbated COPD and depression warrants screening: a systematic review. Eur Respir Rev. 2017;26(144):144. doi:10.1183/16000617.0026-2017
194. Pooler A, Beech R. Examining the relationship between anxiety and depression and exacerbations of COPD which result in hospital admission: a systematic review. *Int J Chron Obstruct Pulmon Dis*. 2014;9:315–330. doi:10.2147/COPD

195. Al-shair K, Dockry R, Mallia-Milanes B, Kolsum U, Singh D, Vestbo J. Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. *Respir Med*. 2009;103(10):1572–1579. doi:10.1016/j.rmed.2008.11.021

196. Regvat J, Zmitke A, Vegnati M, Kosnik M, Suskovic S. Anxiety and depression during hospital treatment of exacerbation of chronic obstructive pulmonary disease. *J Int Med Res*. 2011;39(3):1028–1038. doi:10.1177/0300060511390033

197. Keating A, Lee A, Holland AE. What prevents people with chronic obstructive pulmonary disease from attending pulmonary rehabilitation? A systematic review. *Chron Respir Dis*. 2011;8(2):89–99. doi:10.1177/1479972310393756

198. Lee SH, Kim KU, Lee H, Kim YS, Lee MK, Park HK. Factors associated with low-level physical activity in elderly patients with chronic obstructive pulmonary disease. *Korean J Intern Med*. 2018;33(1):130–137. doi:10.3904/kjim.2016.09.00

199. Fritzschke A, Clamor A, von Leupoldt A. Effects of medical and psychological treatment of depression in patients with COPD—a review. *Respir Med*. 2011;105(10):1422–1433. doi:10.1016/j.rmed.2011.05.014

200. Albrecht JS, Khokhar B, Huang T-Y, et al. Adherence and healthcare utilization among older adults with COPD and depression. *Respir Med*. 2017;129:53–58. doi:10.1016/j.rmed.2017.06.002

201. Smith SM, Sonego S, Ketcheson I, Larson JL. A review of the effectiveness of psychological interventions used for anxiety and depression in chronic obstructive pulmonary disease. *BMJ Open Respir Res*. 2014;1(1):e000042. doi:10.1136/bmjresp-2014-000042

202. Devine EC, Pearsy J. Meta-analysis of the effects of psychosocial-educational care in adults with chronic obstructive pulmonary disease. *Patient Educ Couns*. 1996;29(2):167–178. doi:10.1016/0738-3991(96)00862-2

203. Tselibis A, Pachi A, Ilias I, et al. Strategies to improve anxiety and depression in patients with COPD: a mental health perspective. *Neuropsychiatr Dis Treat*. 2016;12:297–328. doi:10.2147/NDT

204. Torres-Sanchez I, Valenza MC, Saez-Roca G, Cabrera-Martos I, Lopez-Torres I, Rodriguez-Torres J. Results of a multimodal program during hospitalization in obese COPD exacerbated patients. *COPD*. 2016;13(1):19–25. doi:10.3109/1541255X.2015.104328

205. Singh B, Mielke MM, Parsaik AK, et al. A prospective study of chronic obstructive pulmonary disease and the risk for mild cognitive impairment. *JAMA Neurol*. 2014;71(5):581–588. doi:10.1001/jama.neurol.2014.94

206. Dodd JW, Charlton RA, van den Broek MD, Jones PW. Cognitive dysfunction in patients hospitalized with acute exacerbation of COPD. *Chest*. 2013;144(1):119–127. doi:10.1378/chest.12-2099

207. Zhang X, Cui X, Shi X, et al. Chronic obstructive pulmonary disease as a risk factor for cognitive dysfunction: a meta-analysis of current studies. *J Alzheimers Dis*. 2016;52(1):101–111. doi:10.3233/JAD-150735

208. Ortampum H, Naldoken S. Brain perfusion abnormalities in chronic obstructive pulmonary disease: comparison with cognitive impairment. *Ann Nucl Med*. 2006;20(2):99–106. doi:10.1007/BF02985621

209. Zheng QQ, Wang Y, Wang XT. Chronic hypoxia-hypercapnia influences cognitive function: a possible new model of cognitive dysfunction in chronic obstructive pulmonary disease. *Med Hypotheses*. 2008;71(1):111–113. doi:10.1016/j.mehy.2008.01.025

210. Chang SS, Chen S, McAvay GJ, Tinetti ME. Effect of coexisting chronic obstructive pulmonary disease and cognitive impairment on health outcomes in older adults. *J Am Geriatr Soc*. 2012;60(10):1839–1846. doi:10.1111/j.1532-5415.2012.04171.x

211. Raffaele A-I, Andreca C, Claudio P, et al. Drawing impairment predicts mortality in severe COPD. *Chest*. 2006;130(6):1687–1694. doi:10.1378/chest.130.6.1687

212. Thakur N, Blane PD, Julian LJ, et al. COPD and cognitive impairment: the role of hypoxemia and oxygen therapy. *Int J Chron Obstruct Pulmon Dis*. 2010;5:263–269. doi:10.2147/copd.s10684

213. Pereira ED, Viana CS, Taunay TC, Sales PU, Lima JW, Holanda MA. Improvement of cognitive function after a three-month pulmonary rehabilitation program for COPD patients. *Lung*. 2011;189(4):279–285. doi:10.1007/s00408-011-9303-6

214. Kozora E, Tran ZV, Make B. Neurobehavioral improvement after brief rehabilitation in patients with chronic obstructive pulmonary disease. *J Cardiopulm Rehabil*. 2002;22(6):426–430. doi:10.1097/00004843-200211000-00008

215. Kenn K, Gloeckl R, Soennichsen A, et al. Predictors of success for pulmonary rehabilitation in patients awaiting lung transplantation. *Transplantation*. 2015;99(5):1072–1077. doi:10.1097/TP.0000000000000472

216. Stephenson A, Seitz DP, Fischer HD, et al. Cholinesterase inhibitors and adverse pulmonary events in older people with chronic obstructive pulmonary disease and concomitant dementia: a population-based, cohort study. *Drugs Aging*. 2012;29(3):213–223. doi:10.1165/11599480-0000000000000000

217. Roberts MH, Mapel DW, Hartry A, Von Worley A, Thomson H. Chronic pain and pain medication use in chronic obstructive pulmonary disease. *Chest*. 2011;139:298–309. doi:10.1378/chest.1113914

218. Bentsen SB, Rustoen T, Miaskowski C. Differences in subjective and objective respiratory parameters in patients with chronic obstructive pulmonary disease with and without pain. *Int J Chron Obstruct Pulmon Dis*. 2012;7:137–143. doi:10.2147/COPD

219. Elkington H, White P, Addington-Hall J, Higgs R, Edmonds P. The healthcare needs of chronic obstructive pulmonary disease patients in the last year of life. *Palliat Med*. 2005;19(6):485–491. doi:10.1177/026992160505106a

220. Lohne V, Heer HC, Andersen M, Miaskowski C, Kongerud J, Rustoen T. Qualitative study of pain in patients with chronic obstructive pulmonary disease. *Heart Lung*. 2010;39(3):226–234. doi:10.1116/11599480-0000000000000000

221. van Dam van Isselt EF, Groenewegen-Sipkema KH, Spruit-van Eijk M, et al. Pain in patients with COPD: a systematic review and meta-analysis. *BMJ Open*. 2014;4(9):e005898. doi:10.1136/bmjopen-2014-005898

222. Blinderman CD, Homel P, Billings JA, Tennstedt S, Portenoy RK. Symptom distress and quality of life in patients with advanced chronic obstructive pulmonary disease. *J Pain Symptom Manage*. 2009;38(1):115–123. doi:10.1016/j.jpainsymman.2008.07.006

223. Borge CR, Wahl AK, Moun T. Pain and quality of life with chronic obstructive pulmonary disease. *Heart Lung*. 2011;40(3):e90–101. doi:10.1016/j.hrtlng.2010.10.009

224. Bentsen SB, Rustoen T, Miaskowski C. Prevalence and characteristics of pain in patients with chronic obstructive pulmonary disease compared to the Norwegian general population. *J Pain*. 2011;12(5):539–545. doi:10.1016/j.jpainsym.2010.10.014

225. HajGhanbari B, Garland SJ, Road JD, Reid WD. Pain and physical performance in people with COPD. *Respir Med*. 2013;107(11):1692–1699. doi:10.1016/j.rmed.2013.06.010

226. Borge CR, Wahl AK, Moun T. Association of breathlessness with multiple symptoms in chronic obstructive pulmonary disease. *J Adv Nurs*. 2010;66(12):2688–2700. doi:10.1111/j.1365-2648.2010.05447.x
227. Tan G, Jensen MP, Thomby JJ, Shanti BF. Validation of the brief pain inventory for chronic nonmalignant pain. J Pain. 2004;5(2):133–137. doi:10.1016/j.jpain.2003.12.005

228. Rashiq S, Dick BD. Factors associated with chronic nonancer pain in the Canadian population. Pain Res Manage. 2009;14(6):454–460. doi:10.1155/2009/919628

229. Janssen DJ, Spruit MA, Uszko-Lencer NH, Schols JM, Wouters EF. Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure. J Palliat Med. 2011;14(6):735–743. doi:10.1089/jpam.2010.0479

230. Mapel DW, Drotto MP, Marton JP, Woodruff K, Make B. Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data. BMC Health Serv Res. 2011;11(1):43. doi:10.1186/1472-6963-11-43

231. Verberkt CA, van den Beuken-van Everdingen MHJ, Schols J, et al. Respiratory adverse effects of opioids for breathlessness: a systematic review and meta-analysis. Eur Respir J. 2017;50(5):5. doi:10.1183/13993003.01153-2017

232. Ekstrom M, Bajwah S, Bland JM, Currow DC, Hassan J, Johnson MJ. One evidence base; three stories: do opioids relieve chronic breathlessness? Thorax. 2018;73(1):88–90. doi:10.1136/thoraxjnl-2016-209868

233. Ekstrom MP, Bornefalk-Hermansson A, Abernethy AP, Currow DC. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ. 2014;348:g445. doi:10.1136/bmj.g445

234. Gruber EM, Tschernko EM. Anaesthesia and postoperative analgesia in older patients with chronic obstructive pulmonary disease: special considerations. Drugs Aging. 2003;20(5):347–360. doi:10.2165/00002512-200320050-00004

235. Kaelin M, Swank A, Barnard K, Adams K, Beach P, Newman J. Physical fitness and quality of life outcomes in a pulmonary rehabilitation program utilizing symptom limited interval training and resistance training. J Exerc Physiol Online. 2001;4:3.

236. Boueri FM, Bucher-Bartelson BL, Glenn KA, Make B. Quality of life measured with a generic instrument (Short Form-36) improves following pulmonary rehabilitation in patients with COPD. Chest. 2001;119(1):77–84. doi:10.1378/chest.119.1.77

237. De Torres JP, Pinto-Plata V, Ingenito E, et al. Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. Chest. 2002;121(4):1092–1098. doi:10.1378/chest.121.4.1092

238. Yohannes AM, Ershler WB. Anemia in COPD: a systematic review of the prevalence, quality of life, and mortality. Respir Care. 2011;56(5):644–652. doi:10.4187/respcare.01002

239. Silverberg DS, Mor R, Weu MT, Schwartz D, Schwartz IF, Chernin G. Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron. BMC Pulm Med. 2014;14:24. doi:10.1186/1471-2466-14-24

240. Krishnan G, Grant BJ, Muti PC, et al. Association between anemia and quality of life in a population sample of individuals with chronic obstructive pulmonary disease. BMC Med. 2006;4(1):23. doi:10.1186/1471-2466-6-23

241. Chambellan A, Chailleux E, Similowski T. Prognostic value of the hemocrit in patients with severe COPD receiving long-term oxygen therapy. Chest. 2005;128(3):1201–1208. doi:10.1378/chest.128.3.1201

242. Portillo K, Belda J, Anton P, Casan P. [High frequency of anemia in COPD patients admitted in a tertiary hospital]. Rev Clin Esp. 2007;207(8):383–387. doi:10.1157/13108755

243. Vasquez A, Logomarsino JV. Anemia in chronic obstructive pulmonary disease and the potential role of iron deficiency. Cepid. 2016;13(1):100–109. doi:10.3109/15412555.2015.1043519

244. Barba R, de Casasola GG, Marco J, et al. Anemia in chronic obstructive pulmonary disease: a readmission prognostic factor. Curr Med Res Opin. 2012;28(4):617–622. doi:10.1185/03007955.2012.675318

245. Halpern MT, Zilberberg MD, Schmier JK, Lau EC, Shorr AF. Anemia, costs and mortality in chronic obstructive pulmonary disease. Cost Eff Resour Alloc. 2006;4(1):17. doi:10.1186/1478-7547-4-17

246. Cote C, Zilberberg MD, Mody SH, Dordelly LJ, Celli B. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J. 2007;29(5):923–929. doi:10.1183/09031936.00137106

247. Haja Mydin H, Murphy S, Clague H, Sridharan K, Taylor IK. Anemia and performance status as prognostic markers in acute hypercapnic respiratory failure due to chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:151–157. doi:10.2147/COPD.S39403

248. Martinez-Rivera C, Portillo K, Munoz-Ferrer A, et al. Anemia is a mortality predictor in hospitalized patients for COPD exacerbation. COPD. 2012;9(3):243–250. doi:10.3109/15412555.2011.647131

249. Rasmussen L, Christensen S, Lenler-Petersen P, Johnsen SP. Anemia and 90-day mortality in COPD patients requiring invasive mechanical ventilation. Clin Epidemiol. 2010;3:1–5. doi:10.2147/CLEPS.S12885

250. Copur AS, Fumabarker A, Molnar J, et al. Role of anemia in home oxygen therapy in chronic obstructive pulmonary disease patients. Am J Ther. 2015;22(5):361–366. doi:10.1097/MJT.0b013e182875f7c

251. Schonhofer B, Bohrer H, Kohler D. Blood transfusion facilitating difficult weaning from the ventilator. Anaesthesia. 1998;53(2):181–184. doi:10.1046/j.1365-2044.1998.00275.x

252. Graat-Verboom L, Wouters EF, Sneenck FW, van den Borne BE, Lunde R, Spruit MA. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J. 2009;34(1):209–218. doi:10.1183/09031936.004008

253. Almagro P, Lopez Garcia F, Cabrera FJ, et al. [Study of the comorbidities in hospitalized patients due to decompensated chronic obstructive pulmonary disease attended in the Internal Medicine Services. ECCO Study]. Rev Clin Esp. 2010;210(3):101–108. doi:10.1016/j.rce.2009.12.002

254. Silva DR, Coelho AC, Dumke A, et al. Osteoporosis prevalence and associated factors in patients with COPD: a cross-sectional study. Respir Care. 2011;56(7):961–968. doi:10.4187/respcare.01056

255. Graat-Verboom L, Spruit MA, van den Borne BE, et al. Correlates of osteoporosis in chronic obstructive pulmonary disease: a underestimated systemic component. Respir Med. 2009;103(8):1143–1151. doi:10.1016/j.rmed.2009.02.014

256. Lee SH, Kwon HY. Prevalence of Osteoporosis in Korean patients with chronic obstructive pulmonary disease and their health-related quality of life according to the Korea National Health and Nutrition Examination Survey 2008–2011. J Bone Metab. 2017;24(4):241–248. doi:10.11005/jbm.2017.24.4.241

257. Lin C-W, Chen Y-Y, Chen Y-J, Liang C-Y, Lin M-S, Chen W. Prevalence, risk factors, and health-related quality of life of osteoporosis in patients with COPD at a community hospital in Taiwan. Int J Chron Obstruct Pulmon Dis. 2015;10:1493–1500. doi:10.2147/COPD.S85432

258. Romme EA, Murchison JT, Edwards LD, et al. CT-measured bone attenuation in patients with chronic obstructive pulmonary disease: relation to clinical features and outcomes. J Bone Miner Res. 2013;28(6):1369–1377. doi:10.1002/jbmr.1873
259. Malinovschi A, Masoero M, Bellocchia M, et al. Severe vitamin D deficiency is associated with frequent exacerbations and hospitalization in COPD patients. *Respir Res*. 2014;15:131. doi:10.1186/s12931-014-0313-0

260. Pascual-Guardia S, Badenes-Bonet D, Martin-Oniyelo C, et al. Hospital admissions and mortality in patients with COPD exacerbations and vertebral body compression fractures. *Int J Chron Obstruct Pulmon Dis*. 2017;12:1837–1845. doi:10.2147/COPD.S117094

261. Hatthöfll J, Gaude GS. Prevalence and correlates of osteoporosis in chronic obstructive pulmonary disease patients in India. *Lung India*. 2014;31(3):221–227. doi:10.4103/0970-2113.135759

262. Kiyokawa H, Muro S, Oguma T, et al. Impact of COPD exacerbations on osteoporosis assessed by chest CT scan. *COPD*. 2012;9(3):235–242. doi:10.3109/15412555.2011.650243

263. Harrison RA, Siminoski K, Vethanayagam D, Majumdar SR. Osteoporosis-related kyphosis and impairments in pulmonary function: a systematic review. *J Bone Miner Res*. 2007;22(3):447–457. doi:10.1359/jbmr.061102

264. Hornikx M, Van Remoortel H, Demeyer H, et al. Inhaled corticosteroids in COPD: a systematic review and meta-analysis of randomised controlled trials and observational studies. *Thorax*. 2011;66(8):699–708. doi:10.1136/thx.2011.160028

265. Mineo TC, Ambrogi V, Mineo D, Fabbri A, Fabbrini E, Massoud R. Bone mineral density improvement after lung volume reduction surgery for severe emphysema. *Chest*. 2005;127(6):1960–1966. doi:10.1378/chest.127.6.1960

266. Allen CS, Yeung JH, Vandermeer B, Homik J. Bisphosphonates for steroid-induced osteoporosis. *Cochrane Database Syst Rev*. 2016;10:Cd001347.

267. Rizkallah J, Man SFP, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and meta-analysis. *Chest*. 2009;135(3):786–793. doi:10.1378/chest.08-1516

268. Recio Iglesias et al. 2016

269. Martínez C, Okajima Y, Murray S, et al. Impact of self-reported gastroesophageal reflux disease in subjects from COPDGene cohort. *Respir Res*. 2014;15:62. doi:10.1186/1465-9921-15-62

270. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids: a meta-analysis of glucocorticoid users: a Bayesian meta-regression leveraging confounding and covariates. *Eur Respir J*. 2013:146148. doi:10.1155/2013/146148

271. Harrison RA, Siminoski K, Vethanayagam D, Majumdar SR. Osteoporosis-related kyphosis and impairments in pulmonary function: a systematic review. *J Bone Miner Res*. 2007;22(3):447–457. doi:10.1359/jbmr.061102

272. Hornikx M, Van Remoortel H, Demeyer H, et al. Inhaled corticosteroids in COPD: a systematic review and meta-analysis of randomised controlled trials and observational studies. *Thorax*. 2011;66(8):699–708. doi:10.1136/thx.2011.160028

273. Mineo TC, Ambrogi V, Mineo D, Fabbri A, Fabbrini E, Massoud R. Bone mineral density improvement after lung volume reduction surgery for severe emphysema. *Chest*. 2005;127(6):1960–1966. doi:10.1378/chest.127.6.1960

274. Allen CS, Yeung JH, Vandermeer B, Homik J. Bisphosphonates for steroid-induced osteoporosis. *Cochrane Database Syst Rev*. 2016;10:Cd001347.

275. Casanova C, Baudet JS, Del Valle Velasco M, et al. Increased gastroesophageal reflux disease in patients with severe COPD. *Eur J Cardiothorac Surg*. 2009;35(6):1223–1230. doi:10.1183/09031936.09031936.00139909

276. López García FPLF. Enfermedades digestivas y enfermedad pulmón obstructiva crónica. [Digestive diseases and chronic obstructive pulmonary disease]. *Med Clin (Bare)*. 2010;11:13–16. Spanish.

277. Rizkallah J, Man SFP, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and meta-analysis. *Chest*. 2009;135(3):786–793. doi:10.1378/chest.08-1516

278. Terada K, Muro S, Sato S, et al. Impact of gastro-esophageal reflux disease on COPD exacerbation. *Thorax*. 2008;63(11):951–955. doi:10.1136/thx.2007.092858

279. Takada K, Matsumoto S, Kojima E, et al. Prospective evaluation of the relationship between acute exacerbations of COPD and gastroesophageal reflux disease diagnosed by questionnaire. *Respir Med*. 2011;105(10):1531–1536. doi:10.1016/j.rmed.2011.03.009

280. Lopez-Encuentra A, Astudillo J, Cerezal J, et al. Prognostic value of chronic obstructive pulmonary disease in 2994 cases of lung cancer. *Eur J Cardiothorac Surg*. 2005;27(1):8–13. doi:10.1016/j.ejcts.2004.09.010

281. Martinez C, Okajima Y, Murray S, et al. Impact of self-reported gastroesophageal reflux disease in subjects from COPDGene cohort. *Respir Res*. 2014;15:62. doi:10.1186/1465-9921-15-62

282. Ingebrigtsen TS, Marott JL, Vestbo J, Nordestgaard BG, Hallas J, Lange J. Gastro-esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease. *Respirology*. 2015;20(1):101–107. doi:10.1111/resp.12420

283. Liang BM, Feng YL. Association of gastroesophageal reflux disease symptoms with stable chronic obstructive pulmonary disease. *Lung*. 2012;190(3):277–282. doi:10.1007/s00408-011-9365-5

284. Garcia Rodriguez LA, Ruizomez A, Martin-Merino E, Johansson S, Wallander M-A. Relationship between gastroesophageal reflux disease and COPD in UK primary care. *Chest*. 2008;134(6):1223–1230. doi:10.1136/thx.2007.090902

285. Del Grande LM, Herbellia FA, Bigatao AM, Jardim JR, Patti MG. Inhaled beta agonist bronchodilator does not affect trans-diaphragmatic pressure gradient but decreases lower esophageal sphincter retention pressure in patients with Chronic Obstructive Pulmonary Disease (COPD) and Gastroesophageal Reflux Disease (GERD). *J Gastrointest Surg*. 2016;20(10):1679–1682. doi:10.1007/s11605-016-3192-1

286. Cui Y, Devillier P, Kaug X, et al. Tiotropium reduction of lung inflammation in a model of chronic gastro-esophageal reflux. *Eur Respir J*. 2010;35(6):1370–1376. doi:10.1183/09031936.00139909

287. Fernández-Ruiz M, Guerra-Vales J. Comorbilidad digestiva y hepatica en la EPOC [Digestive and liver comorbidity in COPD]. *Rev Clin Esp*. 2007;207(Supl1):40–46. Spanish

288. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol*. 2013;108(3):308–328; quiz 329. doi:10.1038/ajg.2012.444

289. Boeree MJ, Peters FT, Postma DS, Kleibeuker JH. No effects of high-dose omeprazole in patients with severe airway hyperresponsiveness and (a)symptomatic gastro-oesophageal reflux. *Eur Respir J*. 1998;11(5):1070–1074. doi:10.1183/09031936.98.11051070

290. Poe RH, Kallay MC. Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment. *Chest*. 2003;123(3):679–684. doi:10.1378/chest.123.3.679

291. Xiong W, Zhang QS, Zhao W, Ding W, Liu JM, Zhao YF. A 12-month follow-up study on the preventive effect of oral lansoprazole on acute exacerbation of chronic obstructive pulmonary disease. *Int J Exp Pathol*. 2016;97(2):107–113. doi:10.1111/iep.12173

292. Pena X, Van Den Eynde E, Mene E, Recio J. EPOC y enfermedad cardiovascular [COPD and cardiovascular disease]. *Rev Clin Esp*. 2007;207(Supl1):14–21. Spanish.
